Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial

Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial

Abstract Background In China, cervical cancer is the fifth most commonly diagnosed cancer, and the outcomes for patients with advanced or recurrent disease are poor. Apatinib, a small molecule inhibitor of vascular endothelial growth factor receptor (VEGFR-2), is an orally bioavailable agent, which...

Full description

Bibliographic Details
Main Authors: Jian-Guo Zhou, Nan-Jing Zhou, Qiong Zhang, Yao-yao Feng, Hang Zhou
Format: Article
Language:English
Published: BMC 2018-09-01
Series:Trials
Subjects:
Apatinib
Advanced
Recurrent
Cervical cancer
Online Access:http://link.springer.com/article/10.1186/s13063-018-2858-2

Internet

http://link.springer.com/article/10.1186/s13063-018-2858-2

Similar Items